Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 5 of 5 for “"prasugrel"”.

  1. Novel Modulators of CD39 and CD73

    … inhibitor of CD39. New mixed inhibitors included prasugrel (pIC50 of 4, IC50 of 100 µM), PSB-0739 (pIC50 of 5.7, IC50 of 2 µM) and elinogrel (pIC50 of 4.1, IC50 of 79.4 µM) for CD39, and AR-C 66096 (pIC50 of 4.3, IC50 of 50.1 µM ), PSB-0739 (pIC50 of 4.6, IC50 of 25.1 µM) for CD73. Elinogrel …

    cambridge Repository record for Novel Modulators of CD39 and CD73 (opens in a new tab)

  2. Improving outcomes in patients with coronary heart disease using national registers and platelet function testing

    … function testing, a loading dose of either prasugrel or ticagrelor on top of a previous loading dose of clopidogrel, did not cause a pharmacodynamic overshoot of platelet inhibition. Treatment delays from first medical contact to PCI exceeding one hour were associated with higher mortality …

    lund Repository record for Improving outcomes in patients with coronary heart disease using national registers and platelet function testing (opens in a new tab)

  3. MOLECULAR PHYSIOLOGY OF THROMBOXANE A2 GENERATION IN PLATELETS

    … weight clopidogrel or 3mg/Kg/body weight prasugrel decreased serum thromboxane levels when compared to the control mice. Pre-treatment of human blood ex vivo with active metabolites of clopidogrel (R361015) or prasugrel (R138727) also led to reduction in thromboxane levels. We also …

    temple Repository record for MOLECULAR PHYSIOLOGY OF THROMBOXANE A2 GENERATION IN PLATELETS (opens in a new tab)

  4. Economic Evaluation of a Point of Care Pharmacogenetic Test (CYP2C19) from an Ontario Perspective

    … allele could be treated with clopidogrel while prasugrel or ticagrelor could be prescribed to patients with a loss of function allele. Pharmacogenetic (PGx) testing could optimize pharmacotherapy (i.e. fewer adverse event rates with PGx option, where results are available in 1 hour) Purpose: To …

    toronto-retro Repository record for Economic Evaluation of a Point of Care Pharmacogenetic Test (CYP2C19) from an Ontario Perspective (opens in a new tab)

  5. Πρωτόκολλο μελέτης προσδιορισμού της αντιδραστικότητας των αιμοπεταλίων με τη συσκευή μέτρησης VerifyNow σε ασθενείς υπό αιμοκάθαρση : σύγκριση της διπλής δόσης κλοπιδογρέλης (150mg) έναντι πρασουγρέλης (10mg)

    Η καρδιαγγειακή νοσηρότητα είναι πολύ υψηλή στους ασθενείς με Χρόνια Νεφρική Νόσο (ΧΝΝ) τελικού σταδίου οι οποίοι υποβάλλονται σε αιμοκάθαρση και πολλοί ασθενείς έχουν ένδειξη χορήγησης αντι-αιμοπεταλικής αγωγής. Παρόλα αυτά, η αυξημένη αντιδραστικότητα των αιμοπεταλίων είναι συχνή σε ασθενείς που …

    patras-thes Repository record for Πρωτόκολλο μελέτης προσδιορισμού της αντιδραστικότητας των αιμοπεταλίων με τη συσκευή μέτρησης VerifyNow σε ασθενείς υπό αιμοκάθαρση : σύγκριση της διπλής δόσης κλοπιδογρέλης (150mg) έναντι πρασουγρέλης (10mg) (opens in a new tab)